Actualizado
Reviewed
Jun. 03, 2021

Appendix B: Drug Characteristics Tables

Characteristics of CD4 Post-Attachment Inhibitor

Appendix B, Table 9. Characteristics of the CD4 Post-Attachment Inhibitor
Generic Name
(Abbreviation)
Trade Name		 Formulation Dosing Recommendations Serum Half-Life Elimination/ Metabolic Pathway Adverse Events
Ibalizumab
(IBA)
Trogarzo		 Trogarzo:
  • Single-dose 2 mL vial containing 200 mg/1.33 mL (150 mg/mL) of ibalizumab
 Trogarzo:
  • Administer a single loading dose of IBA 2,000 mg IV infusion over 30 minutes, followed by a maintenance dose of IBA 800 mg IV infusion over 15 minutes every 2 weeks.
  • See prescribing information for additional instructions for preparing, storing, and administering IBA, and for monitoring patients who are receiving IBA.
 ~64 hours Not well defined

Diarrhea

Dizziness

Nausea

Rash

Hypersensitivity, including anaphylaxis and infusion-related reactions have been reported.
Key: IBA = ibalizumab; IV = intravenous

Appendix B: Drug Characteristics Tables

Characteristics of CD4 Post-Attachment Inhibitor

Appendix B, Table 9. Characteristics of the CD4 Post-Attachment Inhibitor
Generic Name
(Abbreviation)
Trade Name		 Formulation Dosing Recommendations Serum Half-Life Elimination/ Metabolic Pathway Adverse Events
Ibalizumab
(IBA)
Trogarzo		 Trogarzo:
  • Single-dose 2 mL vial containing 200 mg/1.33 mL (150 mg/mL) of ibalizumab
 Trogarzo:
  • Administer a single loading dose of IBA 2,000 mg IV infusion over 30 minutes, followed by a maintenance dose of IBA 800 mg IV infusion over 15 minutes every 2 weeks.
  • See prescribing information for additional instructions for preparing, storing, and administering IBA, and for monitoring patients who are receiving IBA.
 ~64 hours Not well defined

Diarrhea

Dizziness

Nausea

Rash

Hypersensitivity, including anaphylaxis and infusion-related reactions have been reported.
Key: IBA = ibalizumab; IV = intravenous

Download Guidelines

Related Content